Multicenter, open-label, post-authorization safety study (PASS) of elsulfavirine (Elpida®) used in the first-line therapy for HIV-1 infected patients added to standard ART (NNRTI + two NRTIs). HIV Glasgow – Virtual, 5–8 October 2020статья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 6 октября 2021 г.
Аннотация:VM1500A is a novel, potent non-nucleoside reverse transcriptase inhibitor with a unique clinical pharmacokinetic profile and broad-spectrum activity across HIV-1 variants. A 20 mg oral capsule formulation of elsulfavirine (ESV), pro-drug of VM1500A, was approved for marketing in Russia in 2017 for treatment of HIV-1 in combination with two nucleoside reverse transcriptase inhibitors as part of a standard ART regimen, under the brand name Elpida®. The safety and efficacy PASS study of Elpida was initiated in 19 clinical sites across Russia in 2018.